JP2010534706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534706A5 JP2010534706A5 JP2010518631A JP2010518631A JP2010534706A5 JP 2010534706 A5 JP2010534706 A5 JP 2010534706A5 JP 2010518631 A JP2010518631 A JP 2010518631A JP 2010518631 A JP2010518631 A JP 2010518631A JP 2010534706 A5 JP2010534706 A5 JP 2010534706A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- amino
- carbonyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 C 1-3 -alkyl Chemical group 0.000 claims description 49
- 150000001875 compounds Chemical class 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 239000000460 chlorine Substances 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 125000002883 imidazolyl group Chemical group 0.000 claims description 12
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 claims description 8
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- QEDMEHMHIZXWDJ-UHFFFAOYSA-N [(3,5-dichlorophenyl)sulfonyl-(1-pyrimidin-2-yl-2,3-dihydroindol-5-yl)amino]methylphosphonic acid Chemical compound C=1C(Cl)=CC(Cl)=CC=1S(=O)(=O)N(CP(O)(=O)O)C(C=C1CC2)=CC=C1N2C1=NC=CC=N1 QEDMEHMHIZXWDJ-UHFFFAOYSA-N 0.000 claims description 7
- UGTRTIMGESUSRW-UHFFFAOYSA-N [[1-(2-chlorophenyl)-2-oxo-3h-indol-5-yl]-(3,5-dichlorophenyl)sulfonylamino]methylphosphonic acid Chemical compound C=1C(Cl)=CC(Cl)=CC=1S(=O)(=O)N(CP(O)(=O)O)C(C=C1CC2=O)=CC=C1N2C1=CC=CC=C1Cl UGTRTIMGESUSRW-UHFFFAOYSA-N 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000006563 (C1-3) alkylaminocarbonyl group Chemical group 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 4
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 claims description 4
- 125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 claims description 4
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000006842 cycloalkyleneimino group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 229920001774 Perfluoroether Polymers 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007035333A DE102007035333A1 (de) | 2007-07-27 | 2007-07-27 | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| PCT/EP2008/059805 WO2009016118A1 (en) | 2007-07-27 | 2008-07-25 | Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534706A JP2010534706A (ja) | 2010-11-11 |
| JP2010534706A5 true JP2010534706A5 (enExample) | 2011-09-08 |
Family
ID=39863019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518631A Pending JP2010534706A (ja) | 2007-07-27 | 2008-07-25 | 置換アリールスルホニルアミノメチルホスホン酸誘導体、その製法並びにｉ型及びｉｉ型糖尿病の治療におけるその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8357689B2 (enExample) |
| EP (1) | EP2185571A1 (enExample) |
| JP (1) | JP2010534706A (enExample) |
| CA (1) | CA2694098A1 (enExample) |
| DE (1) | DE102007035333A1 (enExample) |
| WO (1) | WO2009016118A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007012284A1 (de) * | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035334A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007042154A1 (de) * | 2007-09-05 | 2009-03-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102008019838A1 (de) * | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US9246108B2 (en) | 2012-12-28 | 2016-01-26 | Dow Global Technologies Llc | Quinoline-benzoxazole derived compounds for electronic films and devices |
| KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| CN105037241B (zh) * | 2015-06-19 | 2018-02-23 | 上海上药新亚药业有限公司 | 1‑(2,6‑二氯苯基)‑2‑吲哚酮的合成工艺 |
| TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| AR107293A1 (es) | 2016-01-05 | 2018-04-18 | Incyte Corp | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g |
| KR102459256B1 (ko) * | 2016-06-23 | 2022-10-25 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 판토테네이트 키나제의 소분자 조절제 |
| US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
| CN111542526B (zh) | 2017-10-18 | 2024-01-09 | 因赛特公司 | 作为PI3K-γ抑制剂的由叔羟基取代的缩合咪唑衍生物 |
| US11667651B2 (en) | 2017-12-22 | 2023-06-06 | Hibercell, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| JP7527967B2 (ja) | 2017-12-27 | 2024-08-05 | セント ジュード チルドレンズ リサーチ ホスピタル，インコーポレイティド | Ｃａｓｔｏｒに関連する障害を治療する方法 |
| CN111818922B (zh) | 2017-12-27 | 2023-06-13 | 圣朱德儿童研究医院有限公司 | 泛酸激酶的小分子调节剂 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| EP3946312A4 (en) | 2019-03-27 | 2023-04-19 | St. Jude Children's Research Hospital | SMALL MOLECULE MODULATORS OF PANK |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254823A (en) | 1991-09-17 | 1993-10-19 | Turbochef Inc. | Quick-cooking oven |
| DE69327572T2 (de) | 1992-05-21 | 2000-06-21 | Otsuka Pharmaceutical Factory, Inc. | Phosphonsäurediester-derivat |
| TW260664B (enExample) | 1993-02-15 | 1995-10-21 | Otsuka Pharma Factory Inc | |
| DE19753522A1 (de) | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma | Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6114532A (en) | 1998-02-03 | 2000-09-05 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals |
| EP1123703B1 (en) | 1998-10-23 | 2004-04-14 | Toray Industries, Inc. | Immunomodulatory drug composition |
| JP2000247949A (ja) | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
| US6465444B2 (en) | 2000-03-22 | 2002-10-15 | Merck Frosst Canada & Co. | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| EP1430894A4 (en) * | 2001-09-05 | 2007-12-12 | Eisai R&D Man Co Ltd | LYMPHOCYTE ACTIVATION INHIBITOR AND REMEDY FOR AUTOIMMUNE DISEASE |
| US7223796B2 (en) | 2002-04-11 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use |
| IL164249A0 (en) | 2002-04-11 | 2005-12-18 | Aventis Pharma Gmbh | Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use |
| US7262220B2 (en) | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
| WO2004007437A1 (de) | 2002-07-11 | 2004-01-22 | Aventis Pharma Deutschland Gmbh | Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| PL373329A1 (en) | 2002-07-12 | 2005-08-22 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| WO2004096237A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| AU2004240946B8 (en) | 2003-05-21 | 2012-01-12 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase |
| ES2222832B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222829B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| EP2316826A1 (en) | 2003-07-30 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutics agents |
| ES2222827B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| EP1513085A1 (en) | 2003-09-08 | 2005-03-09 | Abb Research Ltd. | Method of scheduling maintenance actions |
| JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
| EP1632491A1 (en) | 2004-08-30 | 2006-03-08 | Laboratorios Del Dr. Esteve, S.A. | Substituted indole compounds and their use as 5-HT6 receptor modulators |
| BRPI0515522A (pt) | 2004-09-21 | 2008-07-29 | Athersys Inc | composto, composição farmacêutica. métodos de inibir a ligação de ligandos endógenos ao receptor crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor crth-2 em um animal e de preparar um composto, e, kit |
| WO2006052722A1 (en) | 2004-11-09 | 2006-05-18 | Smithkline Beecham Corporation | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof |
| CA2586363A1 (en) | 2004-11-15 | 2006-05-26 | Ceptyr, Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| WO2007044729A2 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| DE102007007751A1 (de) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20080200461A1 (en) | 2007-02-20 | 2008-08-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| DE102007012284A1 (de) * | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| DE102007035334A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007042154A1 (de) | 2007-09-05 | 2009-03-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2010013849A1 (ja) | 2008-08-01 | 2010-02-04 | 日本ケミファ株式会社 | Ｇｐｒ１１９作動薬 |
| MX2011002053A (es) | 2008-09-02 | 2011-03-30 | Boehringer Ingelheim Int | Derivados de (fenil)-amida de acido 7-(piperacina-1-metil)-1h-indo la-2-carboxilico y compuestos relacionados como inhibidores de quinasa map as p38 para el tratamiento de enfermedades respiratorias. |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| CN102459223B (zh) | 2009-05-15 | 2014-11-05 | 诺华股份有限公司 | 5-吡啶-3-基-1，3-二氢-吲哚-2-酮衍生物及其作为醛固酮合成酶和/或cyp11b1调节剂的用途 |
-
2007
- 2007-07-27 DE DE102007035333A patent/DE102007035333A1/de not_active Withdrawn
-
2008
- 2008-07-25 US US12/669,978 patent/US8357689B2/en active Active
- 2008-07-25 CA CA2694098A patent/CA2694098A1/en not_active Abandoned
- 2008-07-25 EP EP08786464A patent/EP2185571A1/en not_active Withdrawn
- 2008-07-25 JP JP2010518631A patent/JP2010534706A/ja active Pending
- 2008-07-25 WO PCT/EP2008/059805 patent/WO2009016118A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534706A5 (enExample) | ||
| CN103124730B (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| JP2010534707A5 (enExample) | ||
| KR100472126B1 (ko) | 양성자 펌프 억제제의 프로드러그 | |
| ES2397292T3 (es) | Nuevo derivado de indol que tiene actividad inhibidora de cinasa I B | |
| NZ243713A (en) | Amidine, amino and cyano group-containing pyridazine, azole, furan, and thiophene derivatives; preparatory processes and pharmaceutical compositions | |
| EP4011882A1 (en) | 4-substituted aminoisoquinoline derivatives | |
| CN109970745B (zh) | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 | |
| CZ18194A3 (en) | Five-membered heterocycles, processes of their preparations and medicaments in which they are comprised | |
| CN102175786B (zh) | 氨基丙醇衍生物 | |
| AU2016204436A1 (en) | Sulfonamides as TRPM8 modulators | |
| JP2007530459A5 (enExample) | ||
| CA2586105A1 (en) | Aminoquinazolines compounds | |
| JP2002502844A5 (enExample) | ||
| HUT61984A (en) | Process for producing condensed imidazole derivatives and pharmaceutical compositions comprising same | |
| JP2010513319A5 (enExample) | ||
| US20210261542A1 (en) | Compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| HUP0202028A2 (en) | Substituted benzimidazole | |
| JP2012513418A (ja) | ピリダジノン誘導体 | |
| WO2008053863A1 (en) | Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton | |
| CA3012812A1 (en) | Heterocyclic sulfonamide derivative and medicine containing same | |
| HUT62877A (en) | Process for producing 4-amino-1,2,2a,3,4,5-hexahydro-benz/cd/indoles substituted in 6-position with heterocyclic group and pharmaceutical compositions comprising such compounds | |
| JP2007538068A (ja) | 新規な縮合複素環およびそれらの使用 | |
| US7019004B2 (en) | Hydantoin derivatives with affinity for somatostatin receptors | |
| CN103025722B (zh) | 具有2-(杂芳基)氨基取代基的氯苯吩嗪及其抗微生物活性 |